WEKO3
アイテム
{"_buckets": {"deposit": "e881b854-6965-49a1-8255-fdf8d4302029"}, "_deposit": {"created_by": 1, "id": "69127", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "69127"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00069127", "sets": ["28"]}, "author_link": ["678339", "678350", "678338", "678342", "678349", "678351", "678347", "678336", "678346", "678344", "678343", "678345", "678348", "678340", "678337", "678341"], "item_10005_date_7": {"attribute_name": "発表年月日", "attribute_value_mlt": [{"subitem_date_issued_datetime": "2007-10-07", "subitem_date_issued_type": "Issued"}]}, "item_10005_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Introduction: A phase II study of Carbon Ion Radiotherapy (CIRT) for HCC according to a 52.8 cobalt gray equivalent (GyE) /4-fraction/1-week regime was conducted from April 2001 to February 2003. Purpose: To evaluate the efficacy of 4-fraction CIRT for HCC. Methods: Eligibility criteria were as follows: biopsy-proven, recurrent or residual tumor after other treatments or no indication for any other treatment; no prior radiotherapy for target tumors; Child-Pugh grade A or B. Results: Forty-seven patients with chronic liver disease of Child-Pugh grade A in 37, B in 10 were enrolled. The median age at therapy was 69 years. The median tumor size was 3.7 (1.2-7.5)cm in diameter. During a median follow-up of 60 (48-70)months, no treatment-related hepatic failure and death occurred. Incidence of grade 3 early hepatic toxicity in the serum-GPT, ALB, T.BIL, PT and ALP according to NCI-CTC (ver.2) was 0, 11, 0, 2, and 13%, respectively. No other grade 3 or worse adverse effect occurred. In 92% of patients, the Child-Pugh score did not increase by more than 1 point within 1 year after the therapy. Local control rate was 96% at 1 to 5 years. Overall and cause-specific survival rates at 3 and 5 years were 57% and 67%, 34% and 42%, respectively. Those in the 27 patients initially treated with CIRT were 63% and 81%, 40% and 52%, respectively. Conclusion: Four-fraction CIRT for HCC seems to have a promising potential as a new, radical, and minimally invasive therapeutic option for HCC.", "subitem_description_type": "Abstract"}]}, "item_10005_description_6": {"attribute_name": "会議概要(会議名, 開催地, 会期, 主催者等)", "attribute_value_mlt": [{"subitem_description": "ILCA\u0027s First Annual Conference", "subitem_description_type": "Other"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Katou, Hirotoshi"}], "nameIdentifiers": [{"nameIdentifier": "678336", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yamada, Shigeru"}], "nameIdentifiers": [{"nameIdentifier": "678337", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yasuda, Shigeo"}], "nameIdentifiers": [{"nameIdentifier": "678338", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Maeda, Yukiteru"}], "nameIdentifiers": [{"nameIdentifier": "678339", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kamada, Tadashi"}], "nameIdentifiers": [{"nameIdentifier": "678340", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Mizoe, Junetsu"}], "nameIdentifiers": [{"nameIdentifier": "678341", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ootou, Masao"}], "nameIdentifiers": [{"nameIdentifier": "678342", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tsujii, Hirohiko"}], "nameIdentifiers": [{"nameIdentifier": "678343", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "加藤 博敏", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "678344", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "山田 滋", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "678345", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "安田 茂雄", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "678346", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "前田 幸輝", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "678347", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "鎌田 正", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "678348", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "溝江 純悦", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "678349", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "大藤 正雄", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "678350", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "辻井 博彦", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "678351", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "conference object", "resourceuri": "http://purl.org/coar/resource_type/c_c94f"}]}, "item_title": "Phase II Study of 4-fraction Carbon Ion Radiotherapy for Hepatocellular Carcinoma", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Phase II Study of 4-fraction Carbon Ion Radiotherapy for Hepatocellular Carcinoma"}]}, "item_type_id": "10005", "owner": "1", "path": ["28"], "permalink_uri": "https://repo.qst.go.jp/records/69127", "pubdate": {"attribute_name": "公開日", "attribute_value": "2007-10-12"}, "publish_date": "2007-10-12", "publish_status": "0", "recid": "69127", "relation": {}, "relation_version_is_last": true, "title": ["Phase II Study of 4-fraction Carbon Ion Radiotherapy for Hepatocellular Carcinoma"], "weko_shared_id": -1}
Phase II Study of 4-fraction Carbon Ion Radiotherapy for Hepatocellular Carcinoma
https://repo.qst.go.jp/records/69127
https://repo.qst.go.jp/records/6912703f54c4e-e200-41e9-add1-7adfddadbde9
Item type | 会議発表用資料 / Presentation(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2007-10-12 | |||||
タイトル | ||||||
タイトル | Phase II Study of 4-fraction Carbon Ion Radiotherapy for Hepatocellular Carcinoma | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
資源タイプ | conference object | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Katou, Hirotoshi
× Katou, Hirotoshi× Yamada, Shigeru× Yasuda, Shigeo× Maeda, Yukiteru× Kamada, Tadashi× Mizoe, Junetsu× Ootou, Masao× Tsujii, Hirohiko× 加藤 博敏× 山田 滋× 安田 茂雄× 前田 幸輝× 鎌田 正× 溝江 純悦× 大藤 正雄× 辻井 博彦 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Introduction: A phase II study of Carbon Ion Radiotherapy (CIRT) for HCC according to a 52.8 cobalt gray equivalent (GyE) /4-fraction/1-week regime was conducted from April 2001 to February 2003. Purpose: To evaluate the efficacy of 4-fraction CIRT for HCC. Methods: Eligibility criteria were as follows: biopsy-proven, recurrent or residual tumor after other treatments or no indication for any other treatment; no prior radiotherapy for target tumors; Child-Pugh grade A or B. Results: Forty-seven patients with chronic liver disease of Child-Pugh grade A in 37, B in 10 were enrolled. The median age at therapy was 69 years. The median tumor size was 3.7 (1.2-7.5)cm in diameter. During a median follow-up of 60 (48-70)months, no treatment-related hepatic failure and death occurred. Incidence of grade 3 early hepatic toxicity in the serum-GPT, ALB, T.BIL, PT and ALP according to NCI-CTC (ver.2) was 0, 11, 0, 2, and 13%, respectively. No other grade 3 or worse adverse effect occurred. In 92% of patients, the Child-Pugh score did not increase by more than 1 point within 1 year after the therapy. Local control rate was 96% at 1 to 5 years. Overall and cause-specific survival rates at 3 and 5 years were 57% and 67%, 34% and 42%, respectively. Those in the 27 patients initially treated with CIRT were 63% and 81%, 40% and 52%, respectively. Conclusion: Four-fraction CIRT for HCC seems to have a promising potential as a new, radical, and minimally invasive therapeutic option for HCC. | |||||
会議概要(会議名, 開催地, 会期, 主催者等) | ||||||
内容記述タイプ | Other | |||||
内容記述 | ILCA's First Annual Conference | |||||
発表年月日 | ||||||
日付 | 2007-10-07 | |||||
日付タイプ | Issued |